Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2021, 46(7): 587
ISSN 0377-8282
Copyright 2021 Clarivate
CCC: 0377-8282
DOI: 10.1358/dof.2021.46.7.3325410
Innovative early clinical trial designs and development strategies: evolution or revolution? Highlights from The Society for Medicines Research Symposium. Virtual - May 6, 2021
Black, D., Konneh, M., Sykes, A.
Adoption of more innovative study designs has several advantages including flexibility, efficient use of patient numbers at suboptimal doses, speed and an ability to allow adaptation to the trial and/or statistical procedures after initiation without undermining validity and integrity. In addition, it is important to seek involvement of patient advocates early in the clinical trial design process to ensure that patient needs are met and to avoid poor accrual and compliance. Inclusion of well-defined pharmacodynamic and phenotypic biomarkers can also help to aid the critical decision-making process by showing whether the drug is behaving as expected from a biological perspective and take decisions on recommended dose(s) for further development. This type of data can provide the confidence to continue clinical development even in the absence of significant clinical efficacy in these early stages. This virtual, half-day meeting was aimed at students, clinicians and practicing professionals from academia and industry looking to gain an understanding of how these designs and concepts are being applied across many therapeutic areas, including oncology, fibrosis, respiratory and inflammatory diseases. This symposium was held as a virtual half-day meeting and sponsored by Pharmidex and Simbec-Orion.

Full Text: PDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences